HOME >> MEDICINE >> NEWS
New data supports CellCept's position as a world leader in solid organ transplantation

19 May 2004, Basel, Switzerland New data presented this week in over 70 abstracts at the American Transplant Congress in Boston, USA strengthen even further the body of evidence that CellCept (mycophenolate mofetil, MMF) is the most reliable, efficacious, low toxic immunosuppressant for adult and paediatric kidney, heart and liver transplant patients.

The collective data presented at the ATC, in which more than 61,000 transplant patients where studied, demonstrate that CellCept-based therapies have unique benefits for solid organ transplant patients such as:

  • Proven patient survival benefits
  • Lowest toxicity profile
  • The greatest reduction in acute and chronic rejection

"In order for us to choose the best immunosuppressant regimen for our patients, we need to consider acute rejection, long term graft function, minimal toxic side-effects and, most importantly, graft and patient survival", said Prof Meier- Kriesche, University of Florida, Gainsville, FL, USA. "Long term data with meaningful patient numbers, data and experience from our peers, allows us to decide on the best low toxic combination for better outcomes and patient survival. CellCept's 10 years of clinical experience, in addition to early clinical trials, provides us that real world data", he added.

Highlights from the wealth of data presented at ATC
in adult liver transplant patients
Lake R, Chu AH, Steffen BJ, et al. Efficacy of triple therapy with mycophenolate mofetil (MMF), tacrolimus (TACRO) and corticosteroids (CS) compared to TACRO and CS immunosuppression in liver transplantation: an analysis of the US liver transplant experience. Abstract 395, ATC 2004. CellCept reduced acute rejection rates in a study of 11,670 liver transplant patients, when added to a tacrolimus based immunosuppressant regimen. Graft and patient survival significantly improved (p<0.0001), whilst the risk for infect
'"/>

Contact: Cendrine Banerjee-Quetel
cendrine.banerjee-quetel@ketchum.com
44-207-611-3656
Ketchum
19-May-2004


Page: 1 2 3 4 5

Related medicine news :

1. Emergency department study supports giving dehydrated children fluids by mouth
2. Review supports link between HRT and stroke
3. Chamomile tea: New evidence supports health benefits
4. Social supports lessen effects of maltreatment on children vulnerable to depression
5. Study supports the use of mechanical assistance
6. Study supports aggressive treatment of heart patients with cholesterol-lowering medication
7. NCI grant supports Jefferson trial to study test for colorectal cancer recurrence
8. Study supports new theory for nicotines protective effect against neurodegenerative disorders
9. New study supports use of PET scans in early diagnosis of Alzheimers disease
10. Contraception study supports convenience, simplicity
11. International grant supports study related to preventing organ rejection

Post Your Comments:
(Date:11/22/2014)... 23, 2014 BambooFlooringChina.com is a ... has proudly released its new collection of bamboo mats ... up to 29% off. , According to the ... tree-like grass, making it a highly renewable resource. Their bamboo ... a mixing color which comes from natural bamboo with caramel ...
(Date:11/22/2014)... Setria® Glutathione is now available ... for use “as a therapeutically active ingredient in ... Therapeutic Goods (Listing) Notice 2014 (No. 5) - ... Glutathione will be exclusivity distributed in Australia by ... imports fine chemicals to Australian manufacturers. TGA approval ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Discount-Dress.com ... aim of the firm is to increase the company’s online ... introduced a new selection of bridesmaid dresses and announced a ... offer is valid until Dec. 30, 2014. All the dresses ... also inexpensive. , In fact, Discount-Dress.com is very good ...
(Date:11/22/2014)... Nocturia is defined by the International ... individual has to wake at night one or ... Pipeline Review, H2 2014” provides comprehensive information on ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:11/22/2014)... A petition seeking a ban on ... in minimally-invasive hysterectomies and fibroid removal surgeries has gained ... October, Bernstein Liebhard LLP reports. According to Change.org, ... 21st, 2014. That represents an increase of 456 signatures ... to the campaign.* , The campaign to ban uterine ...
Breaking Medicine News(10 mins):Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4
(Date:11/21/2014)... , Nov. 20, 2014  RedRick Technologies, a ... and reading room environment guidance, has helped the ... radiology reading room, which may also serve as ... Penn Medicine. "In line with ... College of Radiology,s Imaging 3.0 ™ initiative, ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014 Depomed, Inc. (NASDAQ: ... at the Piper Jaffray 26 th Annual Healthcare Conference in ... at the Piper Jaffray conference is scheduled for 8:00 am EST ... be webcast, and the webcast can be accessed via the Investor ... recording of the webcast will be archived for 30 days on ...
(Date:11/21/2014)... Texas , Nov. 21, 2014  Lexicon Pharmaceuticals, ... pricing of its previously announced underwritten public offering of ... an effective shelf registration statement. The offering will consist ... offering price of $1.005 per share.  Lexicon has also ... to 7,462,687 additional shares of common stock.  All of ...
Breaking Medicine Technology:RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3
Cached News: